Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers
Szczepanek S, Roberts S, Rogers K, Cotte C, Adami A, Bracken S, Salmon S, Secor E, Thrall R, Andemariam B, Metzger D. Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers. PLOS ONE 2016, 11: e0149261. PMID: 26910228, PMCID: PMC4766082, DOI: 10.1371/journal.pone.0149261.Peer-Reviewed Original ResearchConceptsSickle cell diseaseAnti-pneumococcal antibody titerSCD miceAntibody titersPrevnar-13Pneumococcal vaccinationPneumococcal infectionControl miceSickle cell disease miceIntranasal pneumococcal infectionPoor long-term efficacyLong-term efficacyMouse challenge modelPolysaccharide conjugate vaccinesInitial IgGPneumococcal vaccineIntranasal infectionIgM responseAntibody responseDisease miceImmune protectionPneumococcal polysaccharideSCD groupCell diseaseCommon cause